Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials.

ABSTRACT:

Background

Chlorpromazine (CPZ) remains one of the most common drugs used for people with schizophrenia worldwide, and a benchmark against which other treatments can be evaluated. Quantitative reviews are rare; this one evaluates the effects of chlorpromazine in the treatment of schizophrenia in comparison with placebo.

Methods

We sought all relevant randomised controlled trials (RCT) comparing chlorpromazine to placebo by electronic and reference searching, and by contacting trial authors and the pharmaceutical industry. Data were extracted from selected trials and, where possible, synthesised and random effects relative risk (RR), the number needed to treat (NNT) and their 95% confidence intervals (CI) calculated.

Results

Fifty RCTs from 1955-2000 were included with

SUBMITTER: Adams CE 

PROVIDER: S-EPMC1274318 | biostudies-literature | 2005 Oct

REPOSITORIES: biostudies-literature